NCT04479306 2026-04-16
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
25 trialsNCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT04563871 2026-01-09
BLOSSOM
Samsung Medical Center
Phase 2 Completed
NCT03810807 2025-12-23
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT06613633 2025-04-20
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
Completed
NCT05298176 2025-03-28
COMBINATION
Amsterdam UMC, location VUmc
Phase 2 Completed
NCT03543683 2025-02-27
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03414814 2025-02-11
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Seoul National University Hospital
Phase 2 Completed
NCT04233021 2025-02-03
ORBITAL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT02841579 2025-01-28
AZENT
MedSIR
Phase 2 Completed
NCT03732352 2024-11-12
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT04764214 2024-08-19
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Fudan University
Phase 2 Completed
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT03497767 2024-05-31
OUTRUN
Trans Tasman Radiation Oncology Group
Phase 2 Completed
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT03535363 2024-03-13
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Case Comprehensive Cancer Center
Phase 1 Completed
NCT04965701 2023-11-13
FLOWER
Istituto Oncologico Veneto IRCCS
Completed
NCT03434418 2023-10-17
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Duke University
Phase 2 Completed
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04541407 2023-05-16
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
University of Colorado, Denver
Phase 1 Completed
NCT03790397 2022-06-03
OSIREX
Fundación GECP
Completed
NCT02769286 2021-08-03
LiquidLung-O
Chonnam National University Hospital
Phase 2 Completed
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT02959749 2018-02-14
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2/3 Completed